Monorden diacetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534580

CAS#: 100262-15-5

Description: Monorden diacetate a Hsp90 Inhibitor. Monorden diacetate is a Promising Lead Compound for the Development of Novel Fungicides.

Chemical Structure

img
Monorden diacetate
CAS# 100262-15-5
Instruction

Theoretical Analysis

MedKoo Cat#: 534580
Name: Monorden diacetate
CAS#: 100262-15-5
Chemical Formula: C22H21ClO8
Exact Mass: 448.09
Molecular Weight: 448.852
Elemental Analysis: C, 58.87; H, 4.72; Cl, 7.90; O, 28.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 12772-57-5   100262-15-5  

Synonym: Monorden diacetate

IUPAC/Chemical Name: 6H-Oxireno(E)(2)benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis(acetyloxy)-8-chloro-1a,14,15,15a-tetrahydro-14-methyl-

InChi Key: IKKGJIXZKBEWBG-YDFGWWAZSA-N

InChi Code: InChI=1S/C22H21ClO8/c1-11-8-17-16(31-17)7-5-4-6-14(26)9-15-20(22(27)28-11)18(29-12(2)24)10-19(21(15)23)30-13(3)25/h4-7,10-11,16-17H,8-9H2,1-3H3/b6-4+,7-5+

SMILES Code: O=C(CC1=C(Cl)C(OC(C)=O)=CC(OC(C)=O)=C12)/C=C/C=C/C3C(O3)CC(C)OC2=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 448.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nguyen HTT, Choi S, Kim S, Lee JH, Park AR, Yu NH, Yoon H, Bae CH, Yeo JH, Choi GJ, Son H, Kim JC. The Hsp90 Inhibitor, Monorden, Is a Promising Lead Compound for the Development of Novel Fungicides. Front Plant Sci. 2020 Apr 2;11:371. doi: 10.3389/fpls.2020.00371. PMID: 32300352; PMCID: PMC7144829.


2: Rogala-Koziarska K, Samluk Ł, Nałęcz KA. Amino acid transporter SLC6A14 depends on heat shock protein HSP90 in trafficking to the cell surface. Biochim Biophys Acta Mol Cell Res. 2019 Oct;1866(10):1544-1555. doi: 10.1016/j.bbamcr.2019.07.009. Epub 2019 Jul 18. PMID: 31326539.


3: Qin F, Li Y, Lin R, Zhang X, Mao Z, Ling J, Yang Y, Zhuang X, Du S, Cheng X, Xie B. Antibacterial Radicicol Analogues from Pochonia chlamydosporia and Their Biosynthetic Gene Cluster. J Agric Food Chem. 2019 Jul 3;67(26):7266-7273. doi: 10.1021/acs.jafc.9b01977. Epub 2019 Jun 24. PMID: 31244199.


4: Nascimento TL, Conte TC, Rissato TS, Luna MS, Soares AG, Moriscot AS, Yamanouye N, Miyabara EH. Radicicol enhances the regeneration of skeletal muscle injured by crotoxin via decrease of NF-kB activation. Toxicon. 2019 Sep;167:6-9. doi: 10.1016/j.toxicon.2019.06.011. Epub 2019 Jun 4. PMID: 31173791.


5: Janssens GE, Lin XX, Millan-Ariño L, Kavšek A, Sen I, Seinstra RI, Stroustrup N, Nollen EAA, Riedel CG. Transcriptomics-Based Screening Identifies Pharmacological Inhibition of Hsp90 as a Means to Defer Aging. Cell Rep. 2019 Apr 9;27(2):467-480.e6. doi: 10.1016/j.celrep.2019.03.044. PMID: 30970250; PMCID: PMC6459000.


6: Derf A, Verekar SA, Jain SK, Deshmukh SK, Bharate SB, Chaudhuri B. Radicicol rescues yeast cell death triggered by expression of human α-synuclein and its A53T mutant, but not by human βA4 peptide and proapoptotic protein bax. Bioorg Chem. 2019 Apr;85:152-158. doi: 10.1016/j.bioorg.2018.12.033. Epub 2018 Dec 28. PMID: 30612081.


7: Wang R, Han Z, Liu B, Zhou B, Wang N, Jiang Q, Qiao Y, Song C, Chai J, Chang J. Identification of Natural Compound Radicicol as a Potent FTO Inhibitor. Mol Pharm. 2018 Sep 4;15(9):4092-4098. doi: 10.1021/acs.molpharmaceut.8b00522. Epub 2018 Aug 14. PMID: 30063141.


8: Li CW, Lai TY, Chen BS. Changes of signal transductivity and robustness of gene regulatory network in the carcinogenesis of leukemic subtypes via microarray sample data. Oncotarget. 2018 May 4;9(34):23636-23660. doi: 10.18632/oncotarget.25318. PMID: 29805763; PMCID: PMC5955113.


9: Pecoraro M, Pinto A, Popolo A. Inhibition of Connexin 43 translocation on mitochondria accelerates CoCl2-induced apoptotic response in a chemical model of hypoxia. Toxicol In Vitro. 2018 Mar;47:120-128. doi: 10.1016/j.tiv.2017.11.004. Epub 2017 Nov 16. PMID: 29155206.


10: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis. 2017 Oct 1;38(10):1011-1020. doi: 10.1093/carcin/bgx077. PMID: 28968651.


11: Yang Q, Puhm F, Freissmuth M, Nanoff C. Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition. Cancer Chemother Pharmacol. 2017 Oct;80(4):673-684. doi: 10.1007/s00280-017-3390-x. Epub 2017 Aug 4. PMID: 28779264; PMCID: PMC5608778.


12: Alam Q, Alam MZ, Sait KHW, Anfinan N, Noorwali AW, Kamal MA, Khan MSA, Haque A. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases. Curr Drug Metab. 2017;18(9):868-876. doi: 10.2174/1389200218666170728115606. PMID: 28758577.


13: Xu L, Wu P, Xue J, Molnar I, Wei X. Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. J Nat Prod. 2017 Aug 25;80(8):2215-2223. doi: 10.1021/acs.jnatprod.7b00066. Epub 2017 Jul 27. PMID: 28749671; PMCID: PMC5819736.


14: Bartsch K, Hombach-Barrigah A, Clos J. Hsp90 inhibitors radicicol and geldanamycin have opposing effects on Leishmania Aha1-dependent proliferation. Cell Stress Chaperones. 2017 Sep;22(5):729-742. doi: 10.1007/s12192-017-0800-2. Epub 2017 Apr 28. PMID: 28455612; PMCID: PMC5573691.


15: Schaletzki Y, Kromrey ML, Bröderdorf S, Hammer E, Grube M, Hagen P, Sucic S, Freissmuth M, Völker U, Greinacher A, Rauch BH, Kroemer HK, Jedlitschky G. Several adaptor proteins promote intracellular localisation of the transporter MRP4/ABCC4 in platelets and haematopoietic cells. Thromb Haemost. 2017 Jan 5;117(1):105-115. doi: 10.1160/TH16-01-0045. Epub 2016 Oct 20. PMID: 27761583.


16: Krzemień-Ojak Ł, Góral A, Joachimiak E, Filipek A, Fabczak H. Interaction of a Novel Chaperone PhLP2A With the Heat Shock Protein Hsp90. J Cell Biochem. 2017 Feb;118(2):420-429. doi: 10.1002/jcb.25669. Epub 2016 Oct 17. PMID: 27496612.


17: Kinzel L, Ernst A, Orth M, Albrecht V, Hennel R, Brix N, Frey B, Gaipl US, Zuchtriegel G, Reichel CA, Blutke A, Schilling D, Multhoff G, Li M, Niyazi M, Friedl AA, Winssinger N, Belka C, Lauber K. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. Oncotarget. 2016 Jul 12;7(28):43199-43219. doi: 10.18632/oncotarget.9774. PMID: 27259245; PMCID: PMC5190018.


18: Chen K, Dobson RC, Lucet IS, Young SN, Pearce FG, Blewitt ME, Murphy JM. The epigenetic regulator Smchd1 contains a functional GHKL-type ATPase domain. Biochem J. 2016 Jun 15;473(12):1733-44. doi: 10.1042/BCJ20160189. Epub 2016 Apr 8. PMID: 27059856.


19: Nagashima H. Rubratoxin-B-induced secretion of chemokine ligands of cysteine-cysteine motif chemokine receptor 5 (CCR5) and its dependence on heat shock protein 90 in HL60 cells. Environ Toxicol Pharmacol. 2015 Nov;40(3):997-1000. doi: 10.1016/j.etap.2015.10.012. Epub 2015 Nov 2. PMID: 26595743.


20: Teo RD, Dong SS, Gross Z, Gray HB, Goddard WA 3rd. Computational predictions of corroles as a class of Hsp90 inhibitors. Mol Biosyst. 2015 Nov;11(11):2907-14. doi: 10.1039/c5mb00352k. PMID: 26252737.